Tykerb
Generic name: Lapatinib
Usage of Tykerb
Tykerb is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Tykerb is used to treat a certain type of hormone-related breast cancer that has progressed or spread after treatment with other cancer medicines.
In postmenopausal women, Tykerb is given in combination with a hormonal medicine called Femara (letrozole). In others, Tykerb is given together with a cancer medicine called Xeloda (Capecitabine).
Tykerb side effects
Get emergency medical help if you have signs of an allergic reaction to Tykerb: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Tykerb can cause severe or fatal liver problems. Call your doctor right away if you have: upper stomach pain, itching, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).
Also call your doctor at once if you have:
Common Tykerb side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Tykerb
You should not use Tykerb if you are allergic to lapatinib.
To make sure Tykerb is safe for you, tell your doctor if you have:
Do not use Tykerb if you are pregnant. It could harm the unborn baby or cause birth defects. Use effective birth control to prevent pregnancy while you are using this medicine. Tell your doctor right away if you become pregnant.
It is not known whether lapatinib passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are taking this medicine.
How to use Tykerb
Usual Adult Dose for Breast Cancer:
-HER2-POSITIVE METASTATIC BREAST CANCER (in combination with Xeloda): 1250 mg orally once a day on Days 1 to 21 continuously in repeating 21-day cycles until disease progression or unacceptable toxicity. -HORMONE RECEPTOR-POSITIVE, HER2-POSITIVE METASTATIC BREAST CANCER (in combination with Femara): 1500 mg orally once a day continuously. Comments: -Consult the manufacturer product information for Xeloda and Femara dosing recommendations. -HER2-positive metastatic breast cancer patients should have disease progression on trastuzumab prior to initiation of treatment with this drug in combination with Xeloda. Uses: -In combination with Xeloda for treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. -In combination with Femara for treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.
Warnings
Do not use Tykerb if you are pregnant. It could harm the unborn baby.
Tykerb can cause severe or fatal liver problems.
Call your doctor at once if you have signs of liver problems: upper stomach pain, itching, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).
Before you take lapatinib, tell your doctor if you have heart disease, liver disease, an electrolyte imbalance (low potassium or magnesium), or a personal or family history of Long QT syndrome.
Take Tykerb on an empty stomach. Take this medication for the entire length of time prescribed by your doctor.
What other drugs will affect Tykerb
Tell your doctor about all your current medicines and any you start or stop using, especially:
This list is not complete. Other drugs may interact with lapatinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions